Physiologically based pharmacokinetic modeling of nanoparticles.
暂无分享,去创建一个
Kostas Kostarelos | K. Al‐Jamal | Kostas Kostarelos | J. Reineke | Khuloud T Al-Jamal | Mingguang Li | Mingguang Li | Joshua Reineke
[1] R. Ings,et al. Interspecies scaling and comparisons in drug development and toxicokinetics. , 1990, Xenobiotica; the fate of foreign compounds in biological systems.
[2] J. Kreuter,et al. Distribution and elimination of poly(methyl-2-14C-methacrylate) nanoparticle radioactivity after injection in rats and mice. , 1979, Journal of pharmaceutical sciences.
[3] Meng Wang,et al. Particokinetics and extrapulmonary translocation of intratracheally instilled ferric oxide nanoparticles in rats and the potential health risk assessment. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.
[4] Kostas Kostarelos,et al. Tumor targeting of functionalized quantum dot-liposome hybrids by intravenous administration. , 2009, Molecular pharmaceutics.
[5] M. Prato,et al. Tissue biodistribution and blood clearance rates of intravenously administered carbon nanotube radiotracers. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[6] H. Alpár,et al. Potential use of nanoparticles for transcutaneous vaccine delivery: effect of particle size and charge. , 2004, International journal of pharmaceutics.
[7] H. Swai,et al. In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems. , 2010, Nanomedicine : nanotechnology, biology, and medicine.
[8] Yves-Jacques Schneider,et al. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[9] Ivan Nestorov,et al. Whole-body physiologically based pharmacokinetic models , 2007, Expert opinion on drug metabolism & toxicology.
[10] Ming-Hsien Tsai,et al. Persistent Tissue Kinetics and Redistribution of Nanoparticles, Quantum Dot 705, in Mice: ICP-MS Quantitative Assessment , 2007, Environmental health perspectives.
[11] R. Jain. Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.
[12] M. de la Fuente,et al. Chitosan nanoparticles for drug delivery to the eye , 2009, Expert opinion on drug delivery.
[13] S. Batra,et al. A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs. , 2008, International immunopharmacology.
[14] Saber M Hussain,et al. Modeling the In Vivo Case with In Vitro Nanotoxicity Data , 2008, International journal of toxicology.
[15] J. Hanes,et al. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. , 2009, Advanced drug delivery reviews.
[16] H. Ando,et al. Circulation time and body distribution of protein A-coated amino modified polystyrene nanoparticles in mice , 1995 .
[17] Abderrahim Nemmar,et al. Development of a physiologically based kinetic model for 99m-Technetium-labelled carbon nanoparticles inhaled by humans , 2009, Inhalation toxicology.
[18] Ande Bao,et al. Dynamic Imaging of Functionalized Multi‐Walled Carbon Nanotube Systemic Circulation and Urinary Excretion , 2008 .
[19] M. Qiao,et al. Lectin-conjugated PLGA nanoparticles loaded with thymopentin: ex vivo bioadhesion and in vivo biodistribution. , 2007, Journal of controlled release : official journal of the Controlled Release Society.
[20] Robert Sturm,et al. A computer model for the clearance of insoluble particles from the tracheobronchial tree of the human lung , 2007, Comput. Biol. Medicine.
[21] Nicholas A Peppas,et al. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. , 2006, International journal of pharmaceutics.
[22] E. Nakamura,et al. In vivo biological behavior of a water-miscible fullerene: 14C labeling, absorption, distribution, excretion and acute toxicity. , 1995, Chemistry & biology.
[23] D. Corry,et al. The migration of bronchoalveolar macrophages into hilar lymph nodes. , 1984, The American journal of pathology.
[24] J. Nah,et al. SPION-loaded chitosan-linoleic acid nanoparticles to target hepatocytes. , 2009, International journal of pharmaceutics.
[25] H. Dai,et al. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. , 2020, Nature nanotechnology.
[26] V. Lenaerts,et al. In vivo uptake of polyisobutyl cyanoacrylate nanoparticles by rat liver Kupffer, endothelial, and parenchymal cells. , 1984, Journal of pharmaceutical sciences.
[27] R. Sharma,et al. Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton's lymphoma tumor bearing mice. , 2005, Journal of controlled release : official journal of the Controlled Release Society.
[28] Ralph Weissleder,et al. Binding affinity and kinetic analysis of targeted small molecule-modified nanoparticles. , 2010, Bioconjugate chemistry.
[29] Sai T Reddy,et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines , 2007, Nature Biotechnology.
[30] Dwight Romanovicz,et al. Biodistribution and long-term fate of silver nanoparticles functionalized with bovine serum albumin in rats. , 2010, Metallomics : integrated biometal science.
[31] James A J Fitzpatrick,et al. Sentinel lymph node imaging using quantum dots in mouse tumor models. , 2007, Bioconjugate chemistry.
[32] Si-Shen Feng,et al. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. , 2005, Biomaterials.
[33] Sandra L. Schmid,et al. Regulated portals of entry into the cell , 2003, Nature.
[34] Kostas Kostarelos,et al. The emergence of nanomedicine: a field in the making. , 2006, Nanomedicine.
[35] Gert Storm,et al. Sheddable Coatings for Long-Circulating Nanoparticles , 2007, Pharmaceutical Research.
[36] Chung-Min Liao,et al. Model-based assessment for human inhalation exposure risk to airborne nano/fine titanium dioxide particles. , 2008, The Science of the total environment.
[37] Wei Yang,et al. Inhaled nanoparticles--a current review. , 2008, International journal of pharmaceutics.
[38] M. Dobrovolskaia,et al. Immunological properties of engineered nanomaterials , 2007, Nature Nanotechnology.
[39] R K Jain,et al. Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model. , 1995, Cancer research.
[40] Hugh A. Barton,et al. Database for Physiologically Based Pharmacokinetic (PBPK) Modeling: Physiological Data for Healthy and Health-Impaired Elderly , 2009, Journal of toxicology and environmental health. Part B, Critical reviews.
[41] H. Reynolds,et al. Macrophages and polymorphonuclear neutrophils in lung defense and injury. , 1990, The American review of respiratory disease.
[42] Agnes G Oomen,et al. What do we (need to) know about the kinetic properties of nanoparticles in the body? , 2007, Regulatory toxicology and pharmacology : RTP.
[43] Chao‐Nan Xu,et al. Giant negative thermal expansion in magnetic nanocrystals. , 2008, Nature nanotechnology.
[44] R K Jain,et al. Determinants of tumor blood flow: a review. , 1988, Cancer research.
[45] W. D. de Jong,et al. The kinetics of the tissue distribution of silver nanoparticles of different sizes. , 2010, Biomaterials.
[46] J. Cheon,et al. Pharmacokinetic properties and tissue storage of FITC conjugated SA-MnMEIO nanoparticles in mice , 2009 .
[47] M. Ferrari,et al. Quantitative mechanics of endothelial phagocytosis of silicon microparticles , 2009, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[48] Lang Tran,et al. Nanoparticles, human health hazard and regulation , 2010, Journal of The Royal Society Interface.
[49] Akiyoshi Hoshino,et al. Applications of T-lymphoma labeled with fluorescent quantum dots to cell tracing markers in mouse body. , 2004, Biochemical and biophysical research communications.
[50] Hugues Dolgos,et al. Physiologically based pharmacokinetic (PBPK) modeling and simulation: applications in lead optimization. , 2009, Current opinion in drug discovery & development.
[51] J. Bacri,et al. Interaction of Anionic Superparamagnetic Nanoparticles with Cells: Kinetic Analyses of Membrane Adsorption and Subsequent Internalization , 2002 .
[52] W. Deen. What determines glomerular capillary permeability? , 2004, The Journal of clinical investigation.
[53] Elaina M Kenyon,et al. A physiologically based pharmacokinetic model for intravenous and ingested dimethylarsinic acid in mice. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.
[54] Wolfgang Kreyling,et al. Toxicological hazards of inhaled nanoparticles--potential implications for drug delivery. , 2004, Journal of nanoscience and nanotechnology.
[55] V. Fuster,et al. Macrophage-specific lipid-based nanoparticles improve cardiac magnetic resonance detection and characterization of human atherosclerosis. , 2009, JACC. Cardiovascular imaging.
[56] Robert Gelein,et al. EXTRAPULMONARY TRANSLOCATION OF ULTRAFINE CARBON PARTICLES FOLLOWING WHOLE-BODY INHALATION EXPOSURE OF RATS , 2002, Journal of toxicology and environmental health. Part A.
[57] Jim E Riviere,et al. Pharmacokinetics of nanomaterials: an overview of carbon nanotubes, fullerenes and quantum dots. , 2009, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.
[58] J. Finkelstein,et al. Translocation of Inhaled Ultrafine Manganese Oxide Particles to the Central Nervous System , 2006, Environmental health perspectives.
[59] N Hussain,et al. Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. , 2001, Advanced drug delivery reviews.
[60] Håkan Wallin,et al. Kupffer cells are central in the removal of nanoparticles from the organism , 2007, Particle and Fibre Toxicology.
[61] C. Liao,et al. Dynamical coupling of PBPK/PD and AUC-based toxicity models for arsenic in tilapia Oreochromis mossambicus from blackfoot disease area in Taiwan. , 2005, Environmental pollution.
[62] Malcolm Rowland,et al. Lumping of Whole-Body Physiologically Based Pharmacokinetic Models , 1998, Journal of Pharmacokinetics and Biopharmaceutics.
[63] Yuichi Sugiyama,et al. In vitro andin vivo evaluation of the tissue-to-blood partition coefficient for physiological pharmacokinetic models , 1982, Journal of Pharmacokinetics and Biopharmaceutics.
[64] Jim E Riviere,et al. Comparison of quantum dot biodistribution with a blood-flow-limited physiologically based pharmacokinetic model. , 2009, Nano letters.
[65] W. Saltzman,et al. The uptake and intracellular fate of PLGA nanoparticles in epithelial cells. , 2009, Biomaterials.
[66] Frank Caruso,et al. Nanoengineering of Particle Surfaces , 2001 .
[67] Mina Choi,et al. The impact of size on tissue distribution and elimination by single intravenous injection of silica nanoparticles. , 2009, Toxicology letters.
[68] Jayanth Panyam,et al. Dynamics of Endocytosis and Exocytosis of Poly(D,L-Lactide-co-Glycolide) Nanoparticles in Vascular Smooth Muscle Cells , 2003, Pharmaceutical Research.
[69] C Timchalk,et al. A Physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model for the organophosphate insecticide chlorpyrifos in rats and humans. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.
[70] S. Moghimi. Modulation of lymphatic distribution of subcutaneously injected poloxamer 407‐coated nanospheres: the effect of the ethylene oxide chain configuration , 2003, FEBS letters.
[71] Ming-Hsien Tsai,et al. Computational and ultrastructural toxicology of a nanoparticle, Quantum Dot 705, in mice. , 2008, Environmental science & technology.
[72] K. Avgoustakis,et al. Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles. , 2001, International journal of pharmaceutics.
[73] E. Kuempel,et al. Development of a bio-mathematical model in rats to describe clearance, retention and translocation of inhaled nano particles throughout the body , 2009 .
[74] R K Jain,et al. Physiologically based pharmacokinetic modeling: principles and applications. , 1983, Journal of pharmaceutical sciences.
[75] M. Bawendi,et al. Renal clearance of quantum dots , 2007, Nature Biotechnology.
[76] Kazunori Kataoka,et al. PEGylated Nanoparticles for Biological and Pharmaceutical Applications , 2003 .
[77] R M Albrecht,et al. Gastrointestinal persorption and tissue distribution of differently sized colloidal gold nanoparticles. , 2001, Journal of pharmaceutical sciences.
[78] Warren C W Chan,et al. Elucidating the mechanism of cellular uptake and removal of protein-coated gold nanoparticles of different sizes and shapes. , 2007, Nano letters.
[79] Anderson,et al. Biodegradation and biocompatibility of PLA and PLGA microspheres. , 1997, Advanced drug delivery reviews.
[80] Scott E McNeil,et al. Translational considerations for cancer nanomedicine. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[81] Indrajit Roy,et al. In vivo biodistribution and clearance studies using multimodal organically modified silica nanoparticles. , 2010, ACS nano.
[82] M. Hashida,et al. Biliary excretion of polystyrene microspheres depends on the type of receptor-mediated uptake in rat liver. , 2001, Biochimica et biophysica acta.
[83] E. Debefve,et al. Effect of nanoparticle size on the extravasation and the photothrombic activity of meso(p-tetracarboxyphenyl)porphyrin. , 2006, Journal of photochemistry and photobiology. B, Biology.
[84] T. Yanagishita,et al. Fabrication of monodisperse polymer nanoparticles by membrane emulsification using ordered anodic porous alumina. , 2010, Langmuir : the ACS journal of surfaces and colloids.
[85] Petra Krystek,et al. Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. , 2008, Biomaterials.
[86] Ivan Nestorov,et al. Whole Body Pharmacokinetic Models , 2003, Clinical pharmacokinetics.
[87] R. Shukla,et al. Biocompatibility of gold nanoparticles and their endocytotic fate inside the cellular compartment: a microscopic overview. , 2005, Langmuir : the ACS journal of surfaces and colloids.
[88] Stephen T Holgate,et al. Exposure, uptake, distribution and toxicity of nanomaterials in humans. , 2010, Journal of biomedical nanotechnology.
[89] L. Brannon-Peppas,et al. Nanoparticle and targeted systems for cancer therapy. , 2004, Advanced drug delivery reviews.
[90] K. Kwon. Development of physiological pharmacokinetic model , 1987 .
[91] Katharina Landfester,et al. Interaction of nanoparticles with cells. , 2009, Biomacromolecules.
[92] Han-Joo Lee,et al. Antibacterial effect of nanosized silver colloidal solution on textile fabrics , 2003 .
[93] G. Grass,et al. Physiologically-based pharmacokinetic simulation modelling. , 2002, Advanced drug delivery reviews.
[94] M. Botelho,et al. Lymphatic Uptake of Pulmonary Delivered Radiolabelled Solid Lipid Nanoparticles , 2002, Journal of drug targeting.
[95] M F Hoylaerts,et al. Passage of intratracheally instilled ultrafine particles from the lung into the systemic circulation in hamster. , 2001, American journal of respiratory and critical care medicine.
[96] P. Couvreur,et al. Hepatic tissue distribution of doxorubicin-loaded nanoparticles after i.v. administration in reticulosarcoma M 5076 metastasis-bearing mice , 2008, Cancer Chemotherapy and Pharmacology.
[97] A. Webster,et al. Deposition and clearance of monodisperse aerosols in the calf lung: effects of particle size and a mucolytic agent (bromhexine) , 1987, Canadian journal of veterinary research = Revue canadienne de recherche veterinaire.
[98] D. Pouliquen,et al. Biodegradation of magnetite dextran nanoparticles in the rat. A histologic and biophysical study. , 1994, Laboratory investigation; a journal of technical methods and pathology.
[99] M Milanese,et al. Description and simulation of a physiological pharmacokinetic model for the metabolism and enterohepatic circulation of bile acids in man. Cholic acid in healthy man. , 1983, The Journal of clinical investigation.
[100] G. Oberdörster,et al. Nanotoxicology: An Emerging Discipline Evolving from Studies of Ultrafine Particles , 2005, Environmental health perspectives.
[101] P. Couvreur,et al. Lymphatic Targeting of Polymeric Nanoparticles After Intraperitoneal Administration in Rats , 1992, Pharmaceutical Research.
[102] M. Okino,et al. Parameters for Carbamate Pesticide QSAR and PBPK/PD Models for Human Risk Assessment. , 2008, Reviews of environmental contamination and toxicology.
[103] S. Schürch,et al. Interaction of fine particles and nanoparticles with red blood cells visualized with advanced microscopic techniques. , 2006, Environmental science & technology.
[104] Mauro Ferrari,et al. The Transport of Nanoparticles in Blood Vessels: The Effect of Vessel Permeability and Blood Rheology , 2008, Annals of Biomedical Engineering.
[105] Bobbi K Lewis,et al. A model of lysosomal metabolism of dextran coated superparamagnetic iron oxide (SPIO) nanoparticles: implications for cellular magnetic resonance imaging , 2005, NMR in biomedicine.
[106] P. Couvreur,et al. Splenic Trapping of Nanoparticles: Complementary Approaches for In Situ Studies , 1997, Pharmaceutical Research.
[107] Sulin Zhang,et al. Effects of particle size and ligand density on the kinetics of receptor-mediated endocytosis of nanoparticles , 2010 .
[108] Nigel J Walker,et al. Migration of intradermally injected quantum dots to sentinel organs in mice. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.
[109] S. Nie,et al. In vivo cancer targeting and imaging with semiconductor quantum dots , 2004, Nature Biotechnology.
[110] Parag Aggarwal,et al. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. , 2009, Advanced drug delivery reviews.
[111] F. Hindré,et al. Comparative biodistribution of thin‐coated iron oxide nanoparticles TCION: Effect of different bisphosphonate coatings , 2001 .
[112] Z. Tang,et al. Mechanism of Strong Luminescence Photoactivation of Citrate-Stabilized Water-Soluble Nanoparticles with CdSe Cores , 2004 .
[113] P. Choyke,et al. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. , 2008, Nanomedicine.
[114] L Morawska,et al. Environmental tobacco smoke deposition in the human respiratory tract: differences between experimental and theoretical approaches. , 2001, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.
[115] P. Couvreur,et al. Nanoparticles in cancer therapy and diagnosis. , 2002, Advanced drug delivery reviews.
[116] J. Grothaus,et al. Tissue distribution of 20 nm, 100 nm and 1000 nm fluorescent polystyrene latex nanospheres following acute systemic or acute and repeat airway exposure in the rat. , 2009, Toxicology.
[117] M. Wirth,et al. Binding and Uptake of Wheat Germ Agglutinin-Grafted PLGA-Nanospheres by Caco-2 Monolayers , 2004, Pharmaceutical Research.
[118] Yolonda L Colson,et al. Expansile nanoparticles: synthesis, characterization, and in vivo efficacy of an acid-responsive polymeric drug delivery system. , 2009, Journal of the American Chemical Society.
[119] Alexander Star,et al. Biodegradation of single-walled carbon nanotubes through enzymatic catalysis. , 2008, Nano letters.
[120] A. Maruyama,et al. Receptor-mediated cell modulator delivery to hepatocyte using nanoparticles coated with carbohydrate-carrying polymers. , 2001, Biomaterials.
[121] L. C. Wyman,et al. BLOOD FLOW RATES OF INTACT AND REGENERATED RAT ADRENALS DURING STRESS. , 1964, American Journal of Physiology.
[122] K. Avgoustakis,et al. Effect of copolymer composition on the physicochemical characteristics, in vitro stability, and biodistribution of PLGA-mPEG nanoparticles. , 2003, International journal of pharmaceutics.
[123] Brahim Lounis,et al. Cathepsin L digestion of nanobioconjugates upon endocytosis. , 2009, ACS nano.
[124] Tim Morris,et al. Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.
[125] W. Mark Saltzman,et al. Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA , 2009, Nature materials.
[126] Walter Schmitt,et al. Development of a Physiology-Based Whole-Body Population Model for Assessing the Influence of Individual Variability on the Pharmacokinetics of Drugs , 2007, Journal of Pharmacokinetics and Pharmacodynamics.
[127] Y. Nishioka,et al. Lymphatic targeting with nanoparticulate system. , 2001, Advanced drug delivery reviews.
[128] P Couvreur,et al. In vitro evaluation of nanoparticles spleen capture. , 1999, Life sciences.
[129] Baorui Liu,et al. Superior antitumor efficiency of cisplatin-loaded nanoparticles by intratumoral delivery with decreased tumor metabolism rate. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.